Search





Search





Markets
/
Stocks
/
tsha
/

Taysha Gene Therapies Inc

TSHA

Add to Watchlist

5.860USD

-0.015-0.26%

Close 07-31 16:00（ET）Quotes delayed by 15 min

1.87BMarket Cap

LossP/E TTM

Taysha Gene Therapies Inc

5.860

-0.015-0.26%

Financial Summary Income Statement Balance Sheet Cash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial Summary Income Statement Balance Sheet Cash Flow Statement

TSHA Cash Flow Statement

You can access the annual and quarterly cash flow statements of Taysha Gene Therapies Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

FY2021Q2

FY2021Q1

FY2020Q4

FY2020Q3

Operating cash flows (indirect method)

Cash flow from continuing operating activities

-85.64%-40.88M

-45.96%-26.72M

-11.80%-24.17M

6.15%-20.18M

-11.22%-22.02M

-13.59%-18.31M

-20.42%-21.61M

-14.58%-21.50M

1.92%-19.80M

-212.89%-16.12M

37.70%-17.95M

43.73%-18.77M

50.69%-20.18M

135.46%14.28M

9.78%-28.81M

-46.18%-33.35M

-85.79%-40.94M

-102.83%-40.26M

-375.48%-31.93M

---22.82M

---22.04M

---19.85M

---6.72M

Net income from continuing operations

-96.99%-42.41M

-48.26%-27.85M

-28.24%-32.73M

-28.45%-26.88M

10.52%-21.53M

-139.35%-18.79M

78.20%-25.52M

14.92%-20.93M

-36.54%-24.06M

185.68%47.74M

-341.39%-117.09M

27.85%-24.60M

64.98%-17.62M

-10.59%-55.72M

48.18%-26.53M

16.70%-34.09M

-57.12%-50.32M

-175.06%-50.39M

-240.29%-51.19M

---40.93M

---32.02M

---18.32M

---15.04M

Operating gains losses

4.24%295.00K

-1.64%299.00K

-94.43%286.00K

-13.98%277.00K

-12.92%283.00K

-62.70%304.00K

441.92%5.13M

-6.12%322.00K

-1.81%325.00K

-97.78%815.00K

241.88%947.00K

25.64%343.00K

27.31%331.00K

17500.00%36.78M

66.87%277.00K

221.18%273.00K

712.50%260.00K

3383.33%209.00K

--166.00K

--85.00K

--32.00K

--6.00K

----

Other non-cash items

125.23%27.00K

34354.55%3.77M

-46.84%320.00K

332.58%514.00K

-129.40%-107.00K

99.98%-11.00K

-99.42%602.00K

-105.88%-221.00K

184.38%364.00K

-22242.07%-64.21M

44972.93%103.22M

1847.67%3.76M

-91.14%128.00K

-90.13%290.00K

-84.79%229.00K

-0.52%193.00K

-73.75%1.44M

-2.07%2.94M

-49.85%1.51M

--194.00K

--5.50M

--3.00M

Change in working capital

-3.60%-4.37M

-190.09%-6.67M

177.76%4.34M

163.54%2.53M

-776.89%-4.22M

49.72%-2.30M

20.96%-5.58M

-708.92%-3.99M

113.26%623.00K

-115.87%-4.57M

2.66%-7.07M

87.25%-493.00K

-300.30%-4.70M

1322.66%28.82M

-158.09%-7.26M

-129.12%-3.87M

171.73%2.34M

130.94%2.03M

213.81%12.50M

--13.28M

--863.00K

---6.55M

--3.98M

-Change in prepaid expenses

24.52%-794.00K

-360.68%-2.13M

231.04%971.00K

-41.36%482.00K

-51.80%-1.05M

-59.11%819.00K

-121.18%-741.00K

-9.57%822.00K

-73.25%-693.00K

1754.63%2.00M

84.16%3.50M

575.92%909.00K

-247.60%-400.00K

105.90%108.00K

8.45%1.90M

-121.18%-191.00K

106.48%271.00K

69.39%-1.83M

394.45%1.75M

--902.00K

---4.18M

---5.98M

---595.00K

-Change in other current liabilities

100.00%0.00

-171.27%-5.49M

100.00%0.00

-78.60%-1.99M

32.51%-2.30M

43.90%-2.02M

62.33%-1.79M

53.57%-1.11M

27.52%-3.41M

-110.74%-3.60M

---4.75M

---2.40M

---4.71M

--33.56M

--0.00

100.00%0.00

-100.00%0.00

--0.00

---8.00K

---60.00K

--46.00K

Cash from non-recurring investing activities

Cash from operating activities

-85.64%-40.88M

-45.96%-26.72M

-11.80%-24.17M

6.15%-20.18M

-11.22%-22.02M

-13.59%-18.31M

-20.42%-21.61M

-14.58%-21.50M

1.92%-19.80M

-212.89%-16.12M

37.70%-17.95M

43.73%-18.77M

50.69%-20.18M

135.46%14.28M

9.78%-28.81M

-46.18%-33.35M

-85.79%-40.94M

-102.83%-40.26M

-375.48%-31.93M

---22.82M

---22.04M

---19.85M

---6.72M

Investing cash flow

Net cash from continuing investing activities

-93.65%24.00K

12600.00%250.00K

208.57%108.00K

-99.00%2.00K

170.00%378.00K

-111.76%-2.00K

--35.00K

518.75%201.00K

-96.41%140.00K

-99.26%17.00K

-100.00%0.00

-100.61%-48.00K

-53.72%3.90M

-72.08%2.31M

-42.32%2.02M

162.27%7.86M

1478.09%8.43M

16115.69%8.27M

11196.77%3.50M

--3.00M

--534.00K

--51.00K

--31.00K

Capital expenditures

-93.65%24.00K

--250.00K

208.57%108.00K

-99.00%2.00K

170.00%378.00K

----

--35.00K

--201.00K

-96.41%140.00K

-99.26%17.00K

-100.00%0.00

----

-53.72%3.90M

-72.08%2.31M

-42.32%2.02M

162.27%7.86M

1478.09%8.43M

16115.69%8.27M

11196.77%3.50M

--3.00M

--534.00K

--51.00K

--31.00K

Net cash flow from disposal of fixed assets

-93.65%24.00K

12600.00%250.00K

208.57%108.00K

-99.00%2.00K

170.00%378.00K

-111.76%-2.00K

--35.00K

518.75%201.00K

-96.41%140.00K

-99.26%17.00K

-100.00%0.00

-100.61%-48.00K

-53.72%3.90M

-72.08%2.31M

-42.32%2.02M

162.27%7.86M

1478.09%8.43M

16115.69%8.27M

11196.77%3.50M

--3.00M

--534.00K

--51.00K

--31.00K

Net cash flow from other investing activities

-42957.14%-3.00M

-72.73%3.00K

--60.00K

--64.00K

--7.00K

57.14%11.00K

----

111.48%7.00K

-249.00%-3.49M

----

100.00%0.00

75.60%-61.00K

-100.00%-1.00M

95.45%-250.00K

---3.00M

95.83%-250.00K

---500.00K

---5.50M

----

---6.00M

--0.00

Cash from non-current investing activities

Net cash flow from investing activities

-715.09%-3.02M

-2000.00%-247.00K

-37.14%-48.00K

130.85%62.00K

-165.00%-371.00K

230.00%13.00K

99.00%-35.00K

-518.75%-201.00K

96.41%-140.00K

99.58%-10.00K

-15.56%-3.49M

100.59%48.00K

65.87%-3.90M

72.18%-2.37M

24.54%-3.02M

4.53%-8.11M

-2039.89%-11.43M

-40.80%-8.52M

-12809.68%-4.00M

---8.50M

---534.00K

---6.05M

---31.00K

Financing cash flow

Cash flow from continuous financing activities

1467.31%711.00K

13981.23%49.56M

33.39%8.80M

206.93%216.29M

-136.36%-52.00K

91.60%-357.00K

-95.31%6.59M

18591.78%70.47M

94.05%-22.00K

-110.20%-4.25M

136637.86%140.63M

-96.60%377.00K

-245.79%-370.00K

357.63%41.67M

-100.34%-103.00K

--11.07M

---107.00K

714.37%9.11M

-89.07%29.98M

--0.00

---1.48M

--274.18M

Net cash flow from debt Issuance/repayment

----

--0.00

--9.24M

----

---3.45M

----

-100.00%0.00

----

--9.98M

107164.29%29.98M

--0.00

---28.00K

Net cash flow from common stock issuance/repurchase

134.67%176.00K

13534.72%48.37M

-105.50%-370.00K

206.71%216.17M

188.46%75.00K

14.89%-360.00K

-95.22%6.72M

13996.20%70.48M

-48.00%26.00K

-101.41%-423.00K

207057.35%140.73M

-95.72%500.00K

-81.95%50.00K

--29.96M

---68.00K

--11.68M

--277.00K

100.00%0.00

----

---1.48M

--167.16M

Net cash flow from preferred stock issuance/repurchase

----

--0.00

-100.00%0.00

--0.00

--106.78M

Proceeds from stock option exercised by employees

--516.00K

--1.02M

--197.00K

----

Proceeds from issuance of warrants

----

--225.00K

----

Net cash flow from other financing activities

114.96%19.00K

-2000.00%-57.00K

-113.39%-271.00K

1007.69%118.00K

-164.58%-127.00K

100.80%3.00K

-30.93%-127.00K

89.43%-13.00K

88.57%-48.00K

-103.20%-375.00K

-177.14%-97.00K

79.80%-123.00K

-9.38%-420.00K

1439.02%11.70M

---35.00K

---609.00K

---384.00K

---874.00K

----

--263.00K

Net cash from non-recurrent financing activities

Net cash from financing activities

1467.31%711.00K

13981.23%49.56M

33.39%8.80M

206.93%216.29M

-136.36%-52.00K

91.60%-357.00K

-95.31%6.59M

18591.78%70.47M

94.05%-22.00K

-110.20%-4.25M

136637.86%140.63M

-96.60%377.00K

-245.79%-370.00K

357.63%41.67M

-100.34%-103.00K

--11.07M

---107.00K

714.37%9.11M

-89.07%29.98M

--0.00

---1.48M

--274.18M

Net cash flow

Beginning cash balance

127.72%322.53M

87.13%299.94M

79.85%315.36M

-5.84%119.19M

-3.35%141.64M

-3.97%160.29M

267.44%175.34M

91.61%126.58M

61.89%146.54M

351.82%166.91M

-30.72%47.72M

-33.45%66.06M

-40.35%90.52M

-80.70%36.94M

-65.10%68.88M

-56.59%99.27M

-39.61%151.74M

-31.30%191.41M

1662.23%197.37M

--228.68M

--251.25M

--278.63M

--11.20M

Current period cash flow changes

-92.45%-43.19M

221.10%22.59M

-2.40%-15.42M

302.29%196.17M

-12.44%-22.44M

8.46%-18.65M

-112.63%-15.05M

365.85%48.76M

18.38%-19.96M

-138.03%-20.38M

473.27%119.19M

39.65%-18.34M

53.40%-24.45M

235.04%53.57M

-436.06%-31.93M

2.95%-30.39M

-132.50%-52.47M

-44.89%-39.67M

-102.23%-5.96M

---31.31M

---22.57M

---27.38M

--267.43M

Ending cash balance

134.36%279.34M

127.72%322.53M

87.13%299.94M

79.85%315.36M

-5.84%119.19M

-3.35%141.64M

-3.97%160.29M

267.44%175.34M

91.61%126.58M

61.89%146.54M

351.82%166.91M

-30.72%47.72M

-33.45%66.06M

-40.35%90.52M

-80.70%36.94M

-65.10%68.88M

-56.59%99.27M

-39.61%151.74M

-31.30%191.41M

--197.37M

--228.68M

--251.25M

--278.63M

Free cash flow

-82.61%-40.90M

-47.32%-26.97M

-12.12%-24.27M

7.01%-20.18M

-12.34%-22.40M

-13.47%-18.31M

-20.62%-21.65M

-15.66%-21.70M

17.22%-19.94M

-234.81%-16.13M

41.78%-17.95M

54.47%-18.77M

51.21%-24.09M

124.66%11.97M

13.00%-30.83M

-59.67%-41.22M

-118.73%-49.37M

-143.87%-48.53M

-425.20%-35.44M

---25.81M

---22.57M

---19.90M

---6.75M

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Taysha Gene Therapies Inc Generate?



Taysha Gene Therapies Inc generated -93.09M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Taysha Gene Therapies Inc's Operating Cash Flow Change Year Over Year?



Taysha Gene Therapies Inc's operating cash flow increased by -14.61% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does Taysha Gene Therapies Inc Spend on Capital Expenditures?



Taysha Gene Therapies Inc spent 738.00K on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Taysha Gene Therapies Inc's Financing Cash Flow Changed?



Taysha Gene Therapies Inc used 274.59M in financing activities in the latest quarter.

What is free cash flow and why does it matter for TSHA?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was Taysha Gene Therapies Inc’s free cash flow in the latest quarter?



Free cash flow was -93.83M reflecting a -14.99% change from the previous year.